Seralutinib

About Chiesi

Chiesi Farmaceutici is a nearly century-old, family-owned biopharmaceutical company with a strong international footprint, operating in over 30 countries with more than 7,500 employees. Its core therapeutic focus areas are Respiratory, Rare Diseases, and Specialty Care, supported by a global R&D network. A key differentiator is its status as a certified B Corp and Benefit Corporation, embedding sustainability and social responsibility into its corporate DNA with ambitious goals like achieving Net-Zero GHG emissions by 2035.

About Gossamer Bio

Gossamer Bio is a clinical-stage biotech company dedicated to developing transformative therapies for rare diseases, currently centered on its lead asset, seralutinib, for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company's strategy leverages a novel inhaled delivery mechanism to target key disease pathways directly in the lungs. Having advanced seralutinib into pivotal Phase 3 trials, Gossamer represents a high-conviction, binary investment opportunity where near-term value creation is entirely dependent on the clinical and regulatory success of this single program.

About Gossamer Bio

Gossamer Bio is a clinical-stage biotech company dedicated to developing transformative therapies for rare diseases, currently centered on its lead asset, seralutinib, for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company's strategy leverages a novel inhaled delivery mechanism to target key disease pathways directly in the lungs. Having advanced seralutinib into pivotal Phase 3 trials, Gossamer represents a high-conviction, binary investment opportunity where near-term value creation is entirely dependent on the clinical and regulatory success of this single program.

Therapeutic Areas

Other Pulmonary Arterial Hypertension (PAH) Drugs